filmov
tv
Dr. Ravandi on Vadastuximab Talirine Plus Hypomethylating Agents in AML
Показать описание
OncLive
cancer
oncology
Рекомендации по теме
0:01:36
Dr. Ravandi on Vadastuximab Talirine Plus Hypomethylating Agents in AML
0:03:49
Prof. Farhad Ravandi | Vadastuximab talirine + HMA in AML
0:02:52
Results of trial of vadastuximab talirine plus hypomethylating agents in AML
0:07:59
Anjali Advani, MD: Vadastuximab Talirine in Treatment-Naïve CD33-Positive AML
0:04:06
Vosaroxin for relapsed AML: Updates from VALOR
0:01:55
Ruxolitinib plus decitabine in post-MPN AML
0:03:56
Prof. Farhad Ravandi | ASH 2017 | Nivolumab with cytarabine & idarubicin in newly diagnosed AML
0:01:45
Ivosidenib with venetoclax in IDH1-mutated hematological malignancies
0:03:04
The need for new treatment regimens in older AML patients
0:03:16
How Does the Presence of Molecular Markers Affect AML Care?
0:05:33
ASH 2016: AML, CLL and leukaemogenesis latest
0:07:52
Phase III trial shows vosaroxin improves overall survival in acute myeloid leukaemia
0:15:30
2013 Annual Hematology Meeting: Acute Leukemia - Novel agents
0:01:02
Highly targeted medication for AML
0:02:44
Ongoing and future AML research at the Valk Lab
0:02:33
One size does not fit all: AML subtype treatment approaches
0:17:47
Expert Discussions on Antibody-Based Therapy in AML
0:14:03
Debate: Clinical scenarios in AML: Traditional vs targeted therapy - Traditional
0:01:47
Combating AML
0:01:33
Dr. Jabbour on Emerging Subsets in ALL
0:00:53
Reviewing the Latest Treatment Advancements in ALL
0:01:12
Novel ALL treatment strategies: CAR T-cells
1:58:49
AML at the Crossroads
0:00:59
Measurable Residual Disease - What does it mean to be MRD Positive
0:01:36
0:03:49
0:02:52
0:07:59
0:04:06
0:01:55
0:03:56
0:01:45
0:03:04
0:03:16
0:05:33
0:07:52
0:15:30
0:01:02
0:02:44
0:02:33
0:17:47
0:14:03
0:01:47
0:01:33
0:00:53
0:01:12
1:58:49
0:00:59